Retraction Note: Neurotrophic effects of Cerebrolysin in the Mecp2<sup>308/Y</sup> transgenic model of Rett syndrome.
Doppler E, Rockenstein E, Ubhi K, Inglis C, Mante M, Adame A, Crews L, Hitzl M, Moessler H, Masliah E · 2026 · Acta neuropathologica; 2026 Mar
Study findings
Retraction notice for the paper named in this record. The retracted findings are not presented as supporting evidence.
- Population and setting
- Publication-status notice
- Evidence type
- Not classified
- Preparation
- See the original report; formulation details require verification.
- Source language
- eng
- Title source
- Title as recorded in the linked source or index. A separate original-language title has not been transcribed unless shown above.
Study limitations
- This notice is not an additional efficacy study.
- The reason and scope of the retraction require the publisher notice; no reason is inferred here.
- Full methods and risk of bias have not been independently assessed.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Source access and review scope
Indexed record and available abstract checked; full text not reviewed.
Recorded source-check date: 2026-10-07. This date does not imply a completed systematic review.
Citation and original source
Original source: Doppler E, Rockenstein E, Ubhi K, Inglis C, Mante M, Adame A, Crews L, Hitzl M, Moessler H, Masliah E. Retraction Note: Neurotrophic effects of Cerebrolysin in the Mecp2<sup>308/Y</sup> transgenic model of Rett syndrome. Acta neuropathologica; 2026 Mar 2026.
Molekul research summary: https://molekul.io/research/cbl-update-41874695. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry